|
1
|
I. Ciftci H, O. Radwan M, E. Ozturk S, Ulusoy NG, Sozer E, E. Ellakwa D, Ocak Z, Can M, F.S. Ali T, I. Abd-Alla H, Yayli N, Tateishi H, Otsuka M, Fujita M. Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Derivatives: Optimization of Anti-ABL Kinase Activity. Molecules 2019; 24:E3535. [PMID: 31574910 PMCID: PMC6804044 DOI: 10.3390/molecules24193535] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Revised: 09/25/2019] [Accepted: 09/26/2019] [Indexed: 01/04/2023] Open
Abstract
Imatinib, an Abelson (ABL) tyrosine kinase inhibitor, is a lead molecular-targeted drug against chronic myelogenous leukemia (CML). To overcome its resistance and adverse effects, new inhibitors of ABL kinase are needed. Our previous study showed that the benzyl ester of gypsogenin (1c), a pentacyclic triterpene, has anti-ABL kinase and a subsequent anti-CML activity. To optimize its activities, benzyl esters of carefully selected triterpenes (PT1-PT6), from different classes comprising oleanane, ursane and lupane, and new substituted benzyl esters of gypsogenin (GP1-GP5) were synthesized. All of the synthesized compounds were purified and charachterized by different spectroscopic methods. Cytotoxicity of the parent triterpenes and the synthesized compounds against CML cell line K562 was examined; revealing three promising compounds PT5, GP2 and GP5 (IC50 5.46, 4.78 and 3.19 μM, respectively). These compounds were shown to inhibit extracellular signal-regulated kinase (ERK) downstream signaling, and induce apoptosis in K562 cells. Among them, PT5 was identified to have in vitro activity (IC50 = 1.44 μM) against ABL1 kinase, about sixfold of 1c, which was justified by molecular docking. The in vitro activities of GP2 and GP5 are less than PT5, hence they were supposed to possess other more mechanisms of cytotoxicity. In general, our design and derivatizations resulted in enhancing the activity against ABL1 kinase and CML cells.
Collapse
Affiliation(s)
- Halil I. Ciftci
- Department of Drug Discovery, Science Farm Ltd., 1-7-30-805 Kuhonji, Chuo-ku, Kumamoto 862-0976, Japan; (H.I.C.); (M.O.R.)
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (D.E.E.); (M.C.); (H.T.)
| | - Mohamed O. Radwan
- Department of Drug Discovery, Science Farm Ltd., 1-7-30-805 Kuhonji, Chuo-ku, Kumamoto 862-0976, Japan; (H.I.C.); (M.O.R.)
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (D.E.E.); (M.C.); (H.T.)
- Chemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Dokki 12622, Cairo, Egypt;
| | - Safiye E. Ozturk
- Chemistry Department, Faculty of Science, Ege University, Erzene Mahallesi, Genclik Caddesi, Bornova/Izmir 35040, Turkey; (S.E.O.); (N.G.U.); (E.S.)
| | - N. Gokce Ulusoy
- Chemistry Department, Faculty of Science, Ege University, Erzene Mahallesi, Genclik Caddesi, Bornova/Izmir 35040, Turkey; (S.E.O.); (N.G.U.); (E.S.)
| | - Ece Sozer
- Chemistry Department, Faculty of Science, Ege University, Erzene Mahallesi, Genclik Caddesi, Bornova/Izmir 35040, Turkey; (S.E.O.); (N.G.U.); (E.S.)
| | - Doha E. Ellakwa
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (D.E.E.); (M.C.); (H.T.)
- Department of Biochemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Nasr City 11651, Cairo, Egypt
| | - Zeynep Ocak
- Department of Microbiology, Kocaeli State Hospital, Cedit Mahallesi Gunes Cad, Hastane Yolu Sk, Kocaeli 41300, Turkey;
| | - Mustafa Can
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (D.E.E.); (M.C.); (H.T.)
- Department of Engineering Sciences, Faculty of Engineering and Architecture, Izmir Katip Celebi University, Havaalani Sosesi Caddesi No:25, Cigli/Izmir 35620, Turkey
| | - Taha F.S. Ali
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (D.E.E.); (M.C.); (H.T.)
- Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt
| | - Howaida I. Abd-Alla
- Chemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Dokki 12622, Cairo, Egypt;
| | - Nurettin Yayli
- Faculty of Pharmacy, Karadeniz Technical University, Trabzon 61080, Turkey;
| | - Hiroshi Tateishi
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (D.E.E.); (M.C.); (H.T.)
| | - Masami Otsuka
- Department of Drug Discovery, Science Farm Ltd., 1-7-30-805 Kuhonji, Chuo-ku, Kumamoto 862-0976, Japan; (H.I.C.); (M.O.R.)
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (D.E.E.); (M.C.); (H.T.)
| | - Mikako Fujita
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; (D.E.E.); (M.C.); (H.T.)
| |
Collapse
|